Primary peripheral neuroectodermal tumor (PNET) of the adrenal gland: a rare entity.
12E7 Antigen
/ genetics
Adolescent
Adrenal Gland Neoplasms
/ epidemiology
Adrenal Glands
/ pathology
Adult
Child
Child, Preschool
Female
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Male
Middle Aged
Neuroectodermal Tumors, Primitive, Peripheral
/ epidemiology
Prognosis
Sarcoma, Ewing
/ epidemiology
Young Adult
Journal
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
ISSN: 2241-6293
Titre abrégé: J BUON
Pays: Cyprus
ID NLM: 100883428
Informations de publication
Date de publication:
Historique:
entrez:
26
5
2019
pubmed:
28
5
2019
medline:
22
11
2019
Statut:
ppublish
Résumé
Ewing Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET) is a malignant small round cell tumor belonging to the Ewing Sarcoma Family of Tumors. It occurs more commonly in children and young adults. Its localization in the adrenal gland is extremely rare. We reviewed 35 cases of ES/PNET of the adrenal gland reported in the literature and presented our case. Data were collected by searching for ES/PNET and adrenal gland key words on Google Scholar and PubMed in March 2018, including a case diagnosed in our department. We analyzed all reviewed cases for diagnosis, surgical and systemic therapy and outcome. To date 24 articles presenting cases of ES/PNET of the adrenal gland are reported in the literature. We included in our review 35 cases previously described and one new case. Histologically all cases consisted of sheets of small round cells. Immunohistochemistry was also performed in all cases. Most cases stained positive for CD99 and negative for lymphocytic markers. Markers of epithelial differentiation displayed variable results. In all cases tested, characteristic translocations were displayed supporting the diagnosis. All patients but four were treated surgically and the majority received adjuvant therapy. Only very few cases received neoadjuvant chemotherapy. Primary ES/PNET of the adrenal gland is a rare tumor, showing specific morphological, immunohistochemical and cytogenetic characteristics. Treatment consists of surgery, chemotherapy and radiotherapy. Further investigations paired with long term follow-up are necessary to define prognosis for this rare entity.
Substances chimiques
12E7 Antigen
0
CD99 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM